Active Ingredient(s): Tenofovir Alafenamide
FDA Approved: * November 10, 2016
Category: Hepatitis

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Vemlidy Overview

Tenofovir alafenamide (INN/USAN; trade name Vemlidy) is a nucleotide reverse transcriptase inhibitor and a prodrug of tenofovir. It was developed by Gilead Sciences for use in the treatment of HIV infection and chronic hepatitis B, and is applied in the form of tenofovir alafenamide fumarate (TAF). Closely related to the commonly used reverse-transcriptase inhibitor tenofovir disoproxil fumarate (TDF), TAF has greater antiviral activity and better distribution into lymphoid tissues than that ...

Read more Vemlidy Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Vemlidy Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Tenofovir Alafenamide
  • Powder: 40mg, 40mg/scoopful
  • Tablet: 150mg, 200mg, 250mg, 25mg, 300mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Vemlidy: (1 result)

Sorted by National Drug Code
  • 61958-2301 Vemlidy 25 mg Oral Tablet by Gilead Sciences, Inc.

Other drugs which contain Tenofovir Alafenamide or a similar ingredient: (6 results)